Literature DB >> 15186726

Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma.

J-M Brand1, B Meller, K Von Hof, J Luhm, M Bähre, H Kirchner, C Frohn.   

Abstract

The transfusion of natural killer (NK) lymphocytes into patients suffering from malignant diseases is an approach of current interest in the field of immunotherapy. Little is known about the organ distribution, survival, and clearance of donor immune effector cells in cellular therapy, and no reports exist on these important parameters considering NK cells in particular or any other type of allogeneic lymphocytes in humans. In the context of a clinical Phase I/II study we examined the distribution of transfused allogeneic NK cells in patients suffering from renal cell carcinoma. The NK cells were ex vivo cultivated and activated before transfusion. To assess the circulation of the transfused cells in the peripheral blood, we used a nested PCR technique to detect HLA DRB1 alleles of the NK cell donors. Post-transfusion, all patients showed evidence of circulating donor cells for up to 3 days. After 7 days, all donor cells were cleared from the blood to undetectable levels. To assess organ distribution, (111)In-labeled NK cells were injected and monitored by whole-body scintiscans. A distribution to the whole body, with preference for liver, spleen, and bone marrow, was observed after a short initial uptake in the lungs. No activity was observed in lymphatic nodes. A total of 2/4 evaluable metastases showed a clear accumulation of transfused NK cells. The half-life corrected activity in all body compartments remained almost constant over the 6-day observation period in concordance with the absence of any excretion of radioactivity. This may indicate an extended survival of the transfused cells, despite their foreign nature, in the host organism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186726     DOI: 10.1089/154732804323099235

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  19 in total

Review 1.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

2.  Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.

Authors:  Sergei R Guma; Dean A Lee; Yu Ling; Nancy Gordon; Eugenie S Kleinerman
Journal:  Pediatr Blood Cancer       Date:  2014-03-09       Impact factor: 3.167

3.  Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.

Authors:  Kangan Li; Andrew C Gordon; Linfeng Zheng; Weiguo Li; Yang Guo; Jing Sun; Guixiang Zhang; Guohong Han; Andrew C Larson; Zhuoli Zhang
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

Review 4.  Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities.

Authors:  Priyanka Jha; Daniel Golovko; Sukhmine Bains; Daniel Hostetter; Reinhard Meier; Michael F Wendland; Heike E Daldrup-Link
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

5.  (19)F-MRI for monitoring human NK cells in vivo.

Authors:  Myriam N Bouchlaka; Kai D Ludwig; Jeremy W Gordon; Matthew P Kutz; Bryan P Bednarz; Sean B Fain; Christian M Capitini
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

6.  Quantifying the limits of CAR T-cell delivery in mice and men.

Authors:  Liam V Brown; Eamonn A Gaffney; Ann Ager; Jonathan Wagg; Mark C Coles
Journal:  J R Soc Interface       Date:  2021-03-03       Impact factor: 4.118

7.  Anti-West Nile virus activity of in vitro expanded human primary natural killer cells.

Authors:  Mingjie Zhang; Sylvester Daniel; Yong Huang; Caren Chancey; Qingsheng Huang; Ying F Lei; Andriyan Grinev; Howard Mostowski; Maria Rios; Andrew Dayton
Journal:  BMC Immunol       Date:  2010-01-20       Impact factor: 3.615

8.  Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.

Authors:  Masahiro Ohira; Ryuichi Hotta; Yuka Tanaka; Toshiharu Matsuura; Akin Tekin; Gennaro Selvaggi; Rodrigo Vianna; Camillo Ricordi; Phillip Ruiz; Seigo Nishida; Andreas G Tzakis; Hideki Ohdan
Journal:  Cancer Immunol Immunother       Date:  2021-07-19       Impact factor: 6.968

9.  Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.

Authors:  Jeannette Cany; Anniek B van der Waart; Marleen Tordoir; Gerben M Franssen; Basav N Hangalapura; Jolanda de Vries; Otto Boerman; Nicolaas Schaap; Robbert van der Voort; Jan Spanholtz; Harry Dolstra
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

10.  GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.

Authors:  Okjae Lim; Yuna Lee; Hyejin Chung; Jung Hyun Her; Sang Mi Kang; Mi-young Jung; Bokyung Min; Hyejin Shin; Tae Min Kim; Dae Seog Heo; Yu Kyeong Hwang; Eui-Cheol Shin
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.